
Targeted vitamin D did not significantly reduce major cardiovascular events after MI
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
In the pragmatic TARGET-D randomized trial, vitamin D dosing titrated to a serum target did not significantly reduce the composite of death, recurrent myocardial infarction, heart-failure hospitalization, or stroke after myocardial infarction.
What NurseJet pulled from the source
Among 630 participants followed for an average of 4.2 years, major cardiovascular events occurred in 15.7% with targeted vitamin D management and 18.4% with usual care (hazard ratio 0.85, 95% CI 0.58 to 1.24; P=0.40).
Why this matters for nurses
The trial cautions against presenting targeted vitamin D supplementation as a proven strategy for reducing major cardiovascular events after myocardial infarction.
Bedside takeaway
Present vitamin D as prescribed supplementation, not as a replacement for established post-MI secondary prevention.
Key takeaways
- At baseline, 87% of participants had a 25-hydroxyvitamin D level of 40 ng/mL or lower.
- The primary composite outcome and the individual outcomes of death, heart-failure hospitalization, and stroke were not significantly different.
- A lower recurrent-MI rate was a secondary finding and should not override the nonsignificant primary result.
Practice implications
- Reinforce the prescribed secondary-prevention plan and avoid implying that vitamin D replaces therapies with established post-MI benefit.
Limitations & cautions
- Abstract-only summary. The trial included 630 participants, 78.1% were men, the primary confidence interval included benefit and no benefit, and individual secondary outcomes were not the primary endpoint.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
European heart journal (PubMed)
European heart journal (PubMed). Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial.
https://pubmed.ncbi.nlm.nih.gov/42702500/
Professional education only


